Background: Galectin 3, a fibrosis biomarker, has found to have significant prognostic value in predicting all cause mortality in heart failure patients. However, its role in predicting the risk for new onset heart failure is not well established. We conduct a meta-analysis to analyze the correlation of increase in serum Galectin 3 levels from baseline and development of new onset heart failure.
Methods: MEDLINE, EMBASE, CINAHL, Web of Science, meeting abstracts and Cochrane central databases were searched from inception till May 2017. 6 studies were included in the study. Hazard ratio, random effects model was used to estimate the correlation of increase in Galectin 3 levels with development of new onset heart failure. Between studies heterogeneity was assessed by I2 method.
Results: Pooled patient population comprised of 24,297 patients (mean age 59.1 years, 50.6% male). 1444 (5.9%) patients develop new onset heart failure. Mean baseline Galectin 3 levels were 16.7 ug/L. Patients were followed up for mean duration of 5 years. Increase in Galectin 3 levels from baseline was associated with significant increase in risk of new onset heart failure (1.86 [1.36-2.54], p = 0.0002). We noted considerable heterogeneity 80% between studies.
Conclusion: This meta analysis showed that galectin 3 levels were directly associated with risk of new onset heart failure. Therefore, galectin 3 can help in early detection of new onset heart failure and hence can help in providing preventive strategies.